- Published on
KembaraXtra-Medicine – Acute Mesenteric Ischemia (AMI)
Acute mesenteric ischemia (AMI) is the sudden onset of intestinal hypoperfusion involving all or part of the small bowel due to arterial embolism, arterial thrombosis, mesenteric venous thrombosis, or nonocclusive low-flow/vasospastic states. Reduced blood flow leads to ischemia and secondary inflammatory injury, and—if prolonged—progresses to transmural infarction, necrosis, perforation, sepsis, and death. AMI is also termed acute mesenteric ischemia and is coded as ICD-10-CM K55.0 (acute vascular disorders of intestine).
AMI is uncommon but highly lethal. It accounts for roughly 0.09%–0.2% of emergency admissions and carries a 50%–80% mortality, largely because early disease may have minimal exam findings and diagnosis is frequently delayed. Incidence appears to be increasing, likely from an aging population, improved ICU survival of high-risk patients, increased clinician awareness, and improved imaging access. Arterial embolism and thrombosis are more common in older patients, whereas mesenteric venous thrombosis often affects younger age groups.
Risk factors depend on the AMI subtype. For arterial embolism or thrombosis, key risks include advanced age, atherosclerosis, low cardiac output states (notably atrial fibrillation), severe valvular disease, and intraabdominal malignancy. Mesenteric venous thrombosis is associated with hypercoagulable states (acquired or inherited), portal hypertension, abdominal infection, blunt trauma, pancreatitis, portal malignancy, intraabdominal sepsis, smoking, oral contraceptives, and cirrhosis. Nonocclusive mesenteric ischemia (NOMI) is linked to low-flow states and vasoconstriction, including recent cardiac or aortic surgery, dialysis, hypovolemia, shock, and vasoconstrictive medications and illicit drugs (notably cocaine). AMI can still occur rarely with no identifiable risk factors.
The classic clinical presentation is sudden, severe periumbilical abdominal pain “out of proportion” to the physical examination, often with nausea/vomiting and sometimes diarrhea and/or blood per rectum. About one-third present with the triad of abdominal pain, fever, and hemoccult-positive stool. Early abdominal examination may be deceptively benign—sometimes normal—though mild distention or occult blood may be present; an epigastric bruit can occur. Mesenteric venous thrombosis typically presents with a less abrupt onset than acute arterial occlusion. As ischemia progresses, patients can develop gross distention, absent bowel sounds, sepsis, shock, and peritoneal signs. In older adults, mental status changes may be prominent. Peritonitis strongly suggests irreversible ischemia and bowel necrosis and should trigger immediate surgical action without delay.
AMI is conventionally divided into four etiologic groups with distinct mechanisms and typical patterns. Superior mesenteric artery (SMA) embolism often arises from a cardiac source (left atrium in atrial fibrillation, left ventricle with poor ejection fraction, or valves in endocarditis). Emboli commonly lodge 3–10 cm distal to the SMA origin, often sparing the proximal mid-jejunum. SMA thrombosis usually occurs on a background of chronic atherosclerotic stenosis and can be precipitated by hypotension or low-flow states, producing acute-on-chronic occlusion—often at the SMA orifice—with a larger middle-gut territory at risk. NOMI results from profound splanchnic vasoconstriction in shock/low flow or vasoconstrictor exposure and may involve extensive bowel segments. Mesenteric venous thrombosis causes impaired venous outflow (SMV/IMV/portal system), leading to bowel wall edema, distention, increased resistance, and secondary reduction in arterial inflow. Less common causes include mesenteric artery dissection or inflammation.
Approximate frequencies vary by series, but the provided breakdown includes SMA thrombosis (54%–68%), SMA embolus (26%–32%), NOMI (~10%), mesenteric venous thrombosis (~5%), and focal segmental small-intestine ischemia (~5%). Because outcomes worsen rapidly with time, the most important diagnostic “don’t miss” principle is early suspicion, especially in patients with risk factors and disproportionate pain.
The differential diagnosis is broad early on and should include other causes of acute abdominal pain and peritonitis such as perforated peptic ulcer, pancreatitis, early appendicitis, and other intraabdominal catastrophes. Workup begins with rapid stabilization and parallel diagnostic steps. Laboratory abnormalities classically include leukocytosis, metabolic acidosis, elevated D-dimer, and elevated lactate, but these findings are nonspecific and often late. A key pitfall is relying on lactate early: it may be normal initially and rises more reliably after progression toward necrosis. Serum lactate >2 mmol/L correlates with irreversible transmural necrosis, making it more of a severity marker than an early screening test. D-dimer may help: a normal D-dimer can support ruling out AMI, but an elevated D-dimer is nonspecific. Amylase may be elevated in up to half of cases; phosphate may be elevated in many cases, again typically later. If venous thrombosis is suspected, hypercoagulable evaluation (proteins C/S, antithrombin III, factor V Leiden) may guide long-term therapy but typically does not change acute diagnosis.
CT angiography (CTA) with contrast is the current gold-standard imaging test for suspected AMI because it is fast, widely available, and highly accurate (reported 95%–100% accuracy for visceral ischemic syndromes). CTA can identify arterial occlusion, venous thrombosis, bowel wall changes, and alternate diagnoses, and it may detect embolic sources or other pathology. Plain CT findings are often nonspecific and late; portal venous gas and pneumatosis intestinalis are late findings suggesting gangrene/necrosis and mandate urgent surgery. MRI/MRA can detect proximal SMA/celiac obstruction and may be useful in mesenteric venous thrombosis follow-up, but it is slower and can overestimate stenosis; it is not preferred when CTA is available. Plain abdominal radiographs are frequently normal early and are generally not helpful except for late or indirect signs (ileus, bowel wall thickening, pneumatosis, portal venous gas) or when free air is present (which accelerates the need for surgery). Ultrasound is not recommended if CTA is available because it is time-consuming and limited by bowel gas and body habitus. Conventional angiography is now typically reserved for unclear cases after CT/MRI or when used as part of endovascular intervention planning.
Treatment is time-critical and aims to restore perfusion before infarction while supporting physiology and preventing sepsis. Initial management includes aggressive monitoring and hemodynamic support: crystalloid resuscitation and blood products as needed, correction of acidosis, adequate analgesia (often parenteral opioids), broad-spectrum antibiotics covering gram-negative and anaerobic organisms, and nasogastric decompression. Vasopressors should be used cautiously, only when necessary, to avoid worsening mesenteric hypoperfusion and to reduce risk of abdominal compartment syndrome; when inotropic support is needed, agents such as dobutamine, low-dose dopamine, or milrinone may be less detrimental to mesenteric blood flow than potent vasoconstrictors. In the absence of active bleeding, systemic anticoagulation is usually indicated, although ideal timing is uncertain and must be individualized.
Definitive management depends on the AMI subtype and on whether peritoneal signs are present. Peritonitis mandates immediate laparotomy with resection of nonviable bowel and source control—no delay for additional testing. For major SMA embolus without peritoneal signs, embolectomy is considered standard, and depending on anatomy and severity, options may include surgical revascularization, catheter-directed thrombolysis/vasodilators, or systemic anticoagulation. For SMA thrombosis, emergent surgical revascularization is traditionally the treatment of choice, though endovascular stenting may be viable in selected patients and is increasingly used. NOMI is treated by reversing the precipitating low-flow/vasoconstrictive state: optimize volume, cardiac output, and oxygen delivery; reduce or stop vasoconstrictors when possible; and consider catheter-directed papaverine (or other vasodilatory/antispasmodic agents) via angiographic techniques. Newer modalities such as two-dimensional perfusion angiography may help assess perfusion response after intraarterial vasodilator therapy. For mesenteric venous thrombosis, management hinges on exam: if peritoneal signs exist, laparotomy and resection are required; if not, immediate heparin anticoagulation followed by longer-term anticoagulation (often warfarin or other long-term strategy) may be sufficient. A major practical limitation of purely percutaneous approaches is that many patients already have nonviable bowel, necessitating laparotomy even if flow is restored.
A planned “second-look” operation is indicated in most patients, typically 24–48 hours after revascularization, to reassess bowel viability and avoid missed progressive ischemia. Chronic/postdischarge care includes close outpatient follow-up. After endovascular treatment, antiplatelet therapy such as clopidogrel for 3–6 months is commonly used along with surveillance for restenosis using duplex ultrasound or CTA. For venous thrombosis, ongoing anticoagulation is required to prevent recurrence, though the optimal duration depends on whether provoking factors or persistent thrombophilia exist.
Prognosis varies by etiology and timing. Outcomes are generally best in mesenteric venous thrombosis and in acute arterial embolism treated promptly, while they remain poor in arterial thrombosis and NOMI, especially when diagnosis is delayed. Delayed recognition leads to infarction with perforation, sepsis, shock, and death. Early surgical consultation is essential, and there should be no delay when peritoneal signs are present; surgery may also be needed diagnostically when clinical suspicion is high and imaging is not immediately available. Prevention focuses on controlling underlying risk factors—especially atherosclerosis prevention (smoking cessation, blood pressure control, statin therapy when indicated) and appropriate management of arrhythmias and hypercoagulable states to reduce recurrence risk.
Don’t-miss points (quick memory anchors): severe pain with minimal early tenderness, high mortality, CTA early, lactate can be late (but >2 suggests necrosis), peritonitis = dead bowel until proven otherwise, early anticoagulation if no bleeding, antibiotics + NG tube, and “second-look” surgery after revascularization.
0 Comments
